HEMAsavR is a sterile collection and transfer device that helps medical professionals and hospitals collect more viable sterile and anti-coagulated blood to be evaluated for cell salvage processing and return to patients.
There is a potential for blood loss in any surgical procedures. Oftentimes, it is hard to predict who will bleed and its harder to salvage blood efficiently and economically, according to Ecomed.
“Allogenic transfusions are among the costliest contributors to healthcare expenditures,” David Yurek, CEO of Ecomed Solutions, said in a press release. “Reducing the need for allogenic transfusions has a dramatic impact on healthcare costs and patient outcomes. Further, as our healthcare system is strained by shrinking donor pools, HEMAsavR can reduce that burden and improve care by providing a patient’s own blood back to them.”
The company reports that approximately 14 million allogeneic red cell units are transfused per year.
“There is a tremendous opportunity to collect more of the patient’s own blood, and HEMAsavR provides us with an effective way to do that,” Gary Koenig, CEO of Comprehensive Blood Management said. “Allogeneic blood transfusions have long been an integral and necessary part of the healthcare delivery throughout the world, but with HEMAsavR we can decrease the exposure to and risks of transfusion and achieve better patient outcomes while decreasing associated costs. Having HEMAsavR in the OR is a win-win proposition for the patient and hospital.”
HEMAsavR is compatible with surgical suction and ATS systems and is beneficial to cardiac, vascular, orthopedic, organ transplant, trauma, OB/GYN, thoracic, general, neurosurgery and urology procedures.